All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2020: Highlights for polycythemia vera

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Tiziano Barbui, Papa Giovanni XXIII Hospital, Bergamo, IT. We asked about highlights for polycythemia vera (PV) from the 62nd ASH Annual Meeting and Exposition.

ASH 2020: Highlights for polycythemia vera

Barbui outlines three studies on PV therapies. This includes an update for a 5-year study evaluating ropeginterferon alfa-2b, a phase II trial evaluating the novel hepcidin-mimetic PTG-300, and a study observing discontinuation of interferon treatment in patients with PV.